Abstracts Archive - Page 355 of 2607 - ACR Meeting Abstracts

Abstract Number: 0625 • ACR Convergence 2024
Trends, Outcomes, and Predictors of Mortality in Patients with SLE Hospitalized for Influenza
Asim Khanfar¹, Shiamak Cooper², Ali Mohamed³, Tanvi Borse⁴ and Sarah Nalwalla⁵, ¹Rochester General Hospital, Rochester, NY, ²Rochester General Hospital, Irondequoit, NY, ³Internal Medicine Resident, Rochester General Hospital, Rochester, NY, ⁴Parkview Health, Fort Wayne, IN, ⁵Seth GSMC and KEM Hospital, Mumbai, India
Background/Purpose: SLE is a chronic autoinflammatory condition affecting multiple organ systems. Patients with SLE are at a higher risk for infection compared to the general…
Abstract Number: 0654 • ACR Convergence 2024
Corneal Confocal Microscopy: An Ophthalmic Imaging Biomarker for Small Fiber Neuropathy in Systemic Lupus Erythematosus
Miral Gharib¹, Georgios Baloglu Baloglu², Soha Osman¹, Rayaz A.Malik³ and Samar Alemadi⁴, ¹hamad medical corporation, Doha, Qatar, ²Weill Cornell Medicine , Qatar, doha, ³Weill Cornell Medicine , Qatar, doha, Qatar, ⁴Hamad medical corporation, Doha, Qatar
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic multi-system autoimmune disease with frequent neuropsychiatric symptoms associated with poor outcomes. Small fiber neuropathy can cause intolerable…
Abstract Number: 0645 • ACR Convergence 2024
Mortality and Ethnicity in Adults with Systemic Lupus Erythematosus: A Systematic Literature Review and Meta-Analysis
Samir Patel¹, Zijing Yang¹, deepak Nagra¹, Maryam Adas², Mark Russell¹, Sam Norton¹, Chris Wincup³, James Galloway⁴, Kate Bramham² and Patrick Gordon⁵, ¹King's College London, London, England, United Kingdom, ²King's College London, London, United Kingdom, ³King's College Hospital, London, United Kingdom, ⁴Centre for Rheumatic Diseases, King's College London, London, United Kingdom, ⁵nhs, London, United Kingdom
Background/Purpose: Ethnicity and health outcomes are intrinsically interrelated, although mechanisms are complex. Systemic lupus erythematosus (SLE) is a disease with higher incidence in non-White populations…
Abstract Number: 0638 • ACR Convergence 2024
Soluble TNF RII in Lupus Nephritis as a Biomarker of Disease Activity and Treatment Response
Ranjan Gupta¹, Sonam Rajput², Jayanth Kumar² and Dipendra K Mitra², ¹All India Institute of Medical Sciences, New Delhi, Delhi, India, ²All India Institute of Medical Sciences, New Delhi, New Delhi, India
Background/Purpose: Lupus Nephritis (LN) affects almost 60-70% patients of Systemic Lupus Erythematosus (SLE). Conventional markers of renal involvement i.e. proteinuria and renal biopsy have limitations…
Abstract Number: 0649 • ACR Convergence 2024
Urinary Acetylated Albumin as a Biomarker of Nephritis in Patients with Systemic Lupus Erythematosus
Yeo-Jin Lee¹, Eun-Ju Lee², Minji Kim³, Mi-Ra Cho⁴, Soo Min Ahn³, Seokchan Hong⁴, Ji Seon Oh⁴, Chang-Keun Lee⁴, Bin Yoo⁴ and Yong-Gil Kim³, ¹Asan medical center, Seoul, South Korea, ²Asan Institute for Life Sciences, Asan Medical Center, Seoul, Republic of Korea, ³Asan medical center, University of Ulsan College of Medicine, Seoul, Republic of Korea, ⁴Asan Medical Center, Seoul, Republic of Korea
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that affects multi-organ systems, particularly the kidneys. Urine is an ideal source of SLE biomarkers…
Abstract Number: 0648 • ACR Convergence 2024
Prevalence of Pulmonary Complications Among Patients with Systemic Lupus Erythematosus (SLE): A Systematic Review and Meta-analysis
Athanasios Vassilopoulos¹, Stephanos Vassilopoulos², Jasneet Singh², Ingrid Lazaridou², Markos Kalligeros², Eleftherios Mylonakis³ and Anthony M. Reginato⁴, ¹Warren Alpert Medical School of Brown University, Providence, RI, ²Division of Internal Medicine, Warren Alpert Medical School of Brown University, Rhode Island Hospital, Providence, Rhode Island, Providence, RI, ³Department of Medicine, Houston Methodist Hospital, Houston, ⁴Brown University, Providence, RI
Background/Purpose: Pleuritis remains the most common pulmonary manifestation in patients with SLE. The prevalence of other less common complications of SLE such as: interstitial lung…
Abstract Number: 0641 • ACR Convergence 2024
Predictive Validity of Coronary Artery Calcium Scoring in Low Risk Systemic Lupus Erythematous Patients
Katherine Chakrabarti¹, Apurba Chakrabarti², Emily Lewis² and William McCune³, ¹University of Michigan, Ann Arbor, MI, ²University of Michigan Hospital, Ann Arbor, MI, ³U Michigan, Ann Arbor, MI
Background/Purpose: Traditionally, a coronary artery calcium (CAC) score of zero is associated with low rates (0.1-0.2% annualized risk) of major adverse cardiovascular outcomes (MACE). While…
Abstract Number: 0633 • ACR Convergence 2024
Novel LINE-1 Reverse Transcriptase Inhibitors Can Suppress Type I Interferon Responses and Are Promising Therapeutics for Lupus
Wenyan Miao¹, Digna de Bruin², Cedric Arisdakessian¹, Jannik Rousel², Jared Steranka¹, Matthijs Moerland², Eric Jacobson¹, Mehrnaz Gharaee-Kermani³, Liyang Diao¹, Craig Dobry³, Nafeeza Hafeez¹, Brian Desrosiers¹, J. Michelle Kahlenberg³, Heike Keilhack¹, Robert Rissmann², Keith M Wilcoxen¹ and Tessa Niemeyer-van der Kolk², ¹Rome Therapeutics, Boston, MA, ²Centre for Human Drug Research, Leiden, Netherlands, ³University of Michigan, Ann Arbor, MI
Background/Purpose: Long Interspersed Element-1 (LINE-1) retrotransposon encodes for two proteins, ORF1p and ORF2p. ORF1p is a chaperone protein while ORF2p contains reverse transcriptase (RT) and…
Abstract Number: 0595 • ACR Convergence 2024
bDMARD Drug Survival in Combination Therapy with Methotrexate in Psoriatic Arthritis: A Systematic Literature Review and Meta-analysis
Sélina HANNA ABDELMASSIH¹, Tiphaine DUJARDIN², Athan BAILLET¹, Philippe GAUDIN¹ and Xavier ROMAND¹, ¹Centre hospitalier universitaire Grenoble-Alpes, Grenoble, France, ²Hôpital Reine Hortense, Aix-les-Bains, France
Background/Purpose: During the last two decades we’ve witnessed the rising use of biologic disease-modifying antirheumatic drugs (bDMARDs) in the treatment of psoriatic arthritis (PsA), leaving…
Abstract Number: 0594 • ACR Convergence 2024
Real-world Experience of Bimekizumab for Plaque Psoriasis in Adult Patients with Prior Exposure to Interleukin-17 Inhibitors: A 16-week Multicenter Retrospective Review
Siddhartha Sood¹, Alexander Rimke², Brian Rankin³, Abrahim Abduelmula⁴, jorge Georgakopoulos⁴, Khalad Maliyar⁴, Ahmed Bagit⁵, Fernejoy Leung⁶, Alim Devani⁶, Ronald Vender⁷, Jensen Yeung⁴ and Vimal Prajapati³, ¹Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada, ²Dermatology Research Institute, Calgary, AB, Canada, ³Division of Dermatology, Department of Medicine, University of Calgary, Calgary, AB, Canada, ⁴Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Canada, ⁵Temerty Faculty of Medicine, University of Toronto, Toronto, Canada, ⁶Skin Health & Wellness Centre, Calgary, AB, Canada, ⁷Division of Dermatology, Department of Medicine, McMaster University, Hamilton, Canada
Background/Purpose: While biologic switching is common in routine clinical practice, limited information exists on switching within class from another IL-17i to bimekizumab. We conducted a…
Abstract Number: 0666 • ACR Convergence 2024
Interferon-stimulated Genes on Peripheral CD8+ T Cells of SLE Patients Were the Keys for Early Response to BAFF/APRIL-targeted Therapy
Cuiling Fan¹, Shixian Chen² and Juan Li¹, ¹Department of Rheumatology and Immunology, Nanfang Hospital, Southern Medical University, Guangzhou, China, Guangzhou, China (People's Republic), ²Nanfang Hospital, Southern Medical University, guangzhou, China (People's Republic)
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease. BAFF/APRIL-targeted therapy exert therapeutic effects through the inhibition of B-cell activating factor (BAFF) and a…
Abstract Number: 0471 • ACR Convergence 2024
Understanding the Role of the Complement System in Insulin Resistance and Metabolic Syndrome in Patients with Rheumatoid Arthritis
Jose Viotti-Serra¹, Maria Garcia-Gonzalez², Fuensanta Gomez-Bernal¹, Juan Carlos Quevedo-Abeledo³, Miguel Angel Gonzalez-Gay⁴ and ivan Ferraz-Amaro⁵, ¹Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain, ²Hospital Universitario de Canarias, SC Tenerife, Canarias, Spain, ³Hospital Universitario de Gran Canaria Dr Negrín, Las Palmas de GC, Canarias, Spain, ⁴University of Cantabria, Fundación Jimenez Díaz, Madrid, Madrid, Spain, ⁵Rheumatology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain
Background/Purpose: The complement (C) system has been associated with the etiopathogenesis of rheumatoid arthritis (RA). Insulin resistance (IR) and metabolic syndrome are prevalent among RA…
Abstract Number: 0640 • ACR Convergence 2024
7000-Plex Proteomic Screen of Urine for Flare Monitoring and Treatment Response Biomarkers in Active Lupus Nephritis
kamala Vanarsa¹, Yewei Ma², Mohammad Daouk², Vinaika Maruvada², Ramesh Saxena³ and Chandra Mohan⁴, ¹University of Houston, houstton, ²University of Houston, Houston, ³UT Southwestern Medical Center, Dallas, ⁴University of Houston, Houston, TX
Background/Purpose: Lupus nephritis (LN) is a major cause of morbidity and mortality in patients with lupus. Since the kidney biopsy is invasive, better, more predictive…
Abstract Number: 0628 • ACR Convergence 2024
Genetic Determinants of Childhood Onset Systemic Lupus Erythematosus
Meghan Nelson¹, Shanta Murthy², Sushma Maddipatla², Sreekala Shenoy², Lori Ponder³, Subra Kugathasan⁴, Dave Cutler⁵ and Sampath Prahalad⁶, ¹Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, United States of America; Children’s Healthcare of Atlanta, Atlanta, United States of America; National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland; National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland; Department of Human Genetics; Emory University School of Medicine, Atlanta, Georgia, United States of America, Bethesda, MD, ²Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, United States of America, Atlanta, GA, ³Children's Healthcare of Atlanta, Atlanta, GA, ⁴Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, United States of America; Children’s Healthcare of Atlanta, Atlanta, United States of America, Atlanta, GA, ⁵Department of Human Genetics, Emory University School of Medicine, Atlanta, Georgia, United States of America, Atlanta, GA, ⁶Emory + Children's Pediatric Institute, Atlanta, GA
Background/Purpose: Childhood-onset systemic lupus erythematosus (cSLE) is a multisystem autoimmune disease with significant morbidity and mortality. Genome-wide association studies have identified more than 100 variants…
Abstract Number: 0501 • ACR Convergence 2024
How Fast Do JAK-inhibitors, TNF-inhibitors, Abatacept and IL-6 Inhibitors Act in Rheumatoid Arthritis? An International Collaboration of Registers of Rheumatoid Arthritis Patients (the “JAK-pot” Study)
Delphine Sophie Courvoisier¹, Yacine Mrad¹, Denis Mongin¹, Romain Aymon², Roberto Caporali³, Denis Choquette⁴, Catalin Codreanu⁵, Louis Coupal⁴, Doreen Huschek⁶, Kimme Hyrich⁷, Florenzo Iannone⁸, Tore K. Kvien⁹, Monika Mustak¹⁰, Dan Nordstrom¹¹, Nina Trokovic¹², Lucia Otero-Varela¹³, Karel Pavelka¹⁴, Manuel Enrique Pombo Suarez¹⁵, Sella A. Provan¹⁶, Ana Maria Rodrigues¹⁷, Ziga Rotar¹⁸, Prodromos Sidiropoulos¹⁹, Anja Strangfeld²⁰, Jakub Závada¹⁴, Sizheng Zhao²¹, Axel Finckh¹ and Kim Lauper¹, ¹Division of Rheumatology, Geneva University Hospitals, Geneva, Switzerland, ²Division of Rheumatology, Geneva University Hospitals, Collonges-sous-Salève, France, ³Department of Clinical Sciences and Community Health, University of Milan, and Department of Rheumatology and Medical Sciences, ASST Gaetano Pini-CTO, Milan, Italy, ⁴Rhumadata™, Montreal, QC, Canada, ⁵University of Medicine and Pharmacy, Bucharest, Romania, ⁶German Rheumatism Research Center (DRFZ) Berlin, Berlin, Germany, ⁷Centre for Musculoskeletal Research, The University of Manchester, Manchester, United Kingdom, ⁸Rheumatology Unit- University of Bari "Aldo Moro", IT, Bari, Italy, ⁹Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, ¹⁰Department of Internal Medicine II, Kaiser Franz Josef Hospital, Vienna, Austria, ¹¹Helsinki University Hospital, Helsinki, Finland, ¹²Department of Medicine and Rheumatology ROB-FIN, Helsinki University Hospital, Helsinki, Finland, ¹³Spanish Society of Rheumatology, Madrid, Spain, ¹⁴Institute of Rheumatology and Charles University, Praha, Czech Republic, ¹⁵Rheumatology Department, Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Spain, ¹⁶Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, Oslo, Norway, ¹⁷Nova Medical School and Hospital dos Lusíadas, Lisbon, Portugal, ¹⁸University Medical Centre Ljubljana and University of Ljubljana, Ljubljana, Slovenia, ¹⁹University of Crete, Laboratory of Rheumatology, Autoimmunity and Inflammation. University Hospital, Rheumatology, Clinical Immunology. Institute of Molecular Biology and Biotechnology, Foundation for Research and Technology, Heraklion, Greece, HERAKLIO, Greece, ²⁰German Rheumatism Research Center (DRFZ) Berlin and Charité University Medicine, Berlin, Germany, ²¹Centre for Musculoskeletal Research, The University of Manchester, Liverpool, United Kingdom
Background/Purpose: JAK-inhibitors (JAKi) have demonstrated a rapid onset of action; however, it is unclear how they compare to other targeted therapies in rheumatoid arthritis (RA).…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].